Phathom Pharmaceuticals, Inc. (PHAT)
Largest Insider Buys in Sector
PHAT Stock Price History Chart
PHAT Stock Performance
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori …
Insider Activity of Phathom Pharmaceuticals, Inc.
Over the last 12 months, insiders at Phathom Pharmaceuticals, Inc. have bought $0 and sold $30.83M worth of Phathom Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Phathom Pharmaceuticals, Inc. have bought $3.19M and sold $23.37M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $19,500 was made by Parikh Asit (director) on 2023‑11‑08.
List of Insider Buy and Sell Transactions, Phathom Pharmaceuticals, Inc.
| 2024-07-15 | Sale | President and Chief Executive | 33,848 0.0663% | $11.72 | $396,699 | 0.00% | ||
| 2024-07-15 | Sale | Chief Operating Officer | 10,901 0.0214% | $11.72 | $127,760 | 0.00% | ||
| 2024-07-15 | Sale | CFO and CBO | 4,325 0.0085% | $11.72 | $50,689 | 0.00% | ||
| 2024-04-08 | Sale | CFO and CBO | 3,435 0.0059% | $11.10 | $38,129 | +4.46% | ||
| 2024-03-22 | Sale | President and Chief Executive | 16,851 0.0238% | $9.11 | $153,513 | +1.91% | ||
| 2024-01-24 | Sale | 10 percent owner | 3.7M 7.8033% | $8.10 | $30M | +59.02% | ||
| 2024-01-19 | Sale | CFO and CBO | 6,307 0.0114% | $7.75 | $48,900 | +43.05% | ||
| 2023-11-20 | Sale | CFO and CBO | 2,127 0.0037% | $7.24 | $15,403 | +38.05% | ||
| 2023-11-08 | director | 2,500 0.0044% | $7.80 | $19,500 | +30.93% | |||
| 2023-11-07 | director | 4,000 0.0067% | $7.76 | $31,040 | +25.00% | |||
| 2023-11-06 | director | 1,000 0.0018% | $8.04 | $8,040 | +28.13% | |||
| 2023-11-01 | Sale | CFO and CBO | 12,492 0.0202% | $8.88 | $110,871 | +5.52% | ||
| 2023-06-02 | Sale | CFO and CBO | 1,960 0.0045% | $11.41 | $22,368 | -13.46% | ||
| 2023-05-22 | Sale | CFO and CBO | 2,110 0.0048% | $12.87 | $27,165 | -24.78% | ||
| 2023-04-11 | Chief Operating Officer | 10,000 0.0243% | $8.26 | $82,600 | +26.97% | |||
| 2023-04-10 | director | 1,000 0.0023% | $7.55 | $7,550 | +29.28% | |||
| 2023-04-06 | Sale | CFO and CBO | 3,439 0.0079% | $7.27 | $25,002 | +34.68% | ||
| 2023-04-06 | President and Chief Executive | 12,919 0.0318% | $7.82 | $101,025 | +34.68% | |||
| 2023-03-01 | Sale | President and Chief Executive | 1,436 0.0033% | $8.54 | $12,265 | +13.21% | ||
| 2023-03-01 | Sale | CFO and CBO | 2,032 0.0047% | $8.53 | $17,335 | +13.21% |
Insider Historical Profitability
| Curran Terrie | President and Chief Executive | 377734 0.5524% | $8.68 | 2 | 6 | +28.29% |
| Nabulsi Azmi | Chief Operating Officer | 240421 0.3516% | $8.68 | 2 | 14 | +23.01% |
| Henderson Molly | CFO and CBO | 99447 0.1454% | $8.68 | 1 | 10 | |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 7284269 10.653% | $8.68 | 1 | 0 | +47.21% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 3115008 4.5556% | $8.68 | 3 | 1 | +53.57% |
Institutional Investor Ownership
| Frazier Life Sciences Management L P | $107.36M | 17.27 | 10.11M | 0% | +$0 | 4.85 | |
| Medicxi Growth I Lp | $79.27M | 12.75 | 7.46M | +98.48% | +$39.33M | 17.65 | |
| The Carlyle Group | $37.1M | 5.97 | 3.5M | 0% | +$0 | 1.59 | |
| Invesco | $33.56M | 5.4 | 3.16M | -0.25% | -$83,515.68 | 0.01 | |
| BlackRock | $29.16M | 4.69 | 2.75M | +2.48% | +$706,113.17 | <0.01 |